Scholarlink

<p>Cancer combination therapy is a novel strategy to circumvent drug resistance in highly metastatic and advanced malignancies. To this end, we designed and synthesized a series of dual-targeting compounds that target tubulin and HDAC6 simultaneously. Out of them, compound named as <b>6-4</b> possessed potent inhibitory activity against tubulin polymerization and strong antiproliferative activity to the cancer cell lines tested. <b>6-4</b> was able to inhibit tubulin polymerization and disrupt the microtubule network of tumor cells. Significant downregulation of tubulin deacetylation was also observed after the treatment of <b>6-4</b> which indicated its inhibition toward HDAC6. Mechanism studies demonstrated that <b>6-4</b> could arrest cell cycle in G2/M phase and induce apoptosis in a dose-dependent manner. In addition, <b>6-4</b> can suppress metastasis of Hela cells, and significantly inhibit the formation of HUVEC tubes. All these results suggest that <b>6-4</b> should be a promising candidate for the treatment of cancer.</p><p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Design, synthesis and antitumor activity study of tubulin/HDAC6 dual targeting inhibitor

  • 期刊论文

  • 发表日期：

    2025年4月24日

查看全文
  • Congcong Zheng,
  • Yi Zhang,
  • Yepeng Luan

摘要

Cancer combination therapy is a novel strategy to circumvent drug resistance in highly metastatic and advanced malignancies. To this end, we designed and synthesized a series of dual-targeting compounds that target tubulin and HDAC6 simultaneously. Out of them, compound named as 6-4 possessed potent inhibitory activity against tubulin polymerization and strong antiproliferative activity to the cancer cell lines tested. 6-4 was able to inhibit tubulin polymerization and disrupt the microtubule network of tumor cells. Significant downregulation of tubulin deacetylation was also observed after the treatment of 6-4 which indicated its inhibition toward HDAC6. Mechanism studies demonstrated that 6-4 could arrest cell cycle in G2/M phase and induce apoptosis in a dose-dependent manner. In addition, 6-4 can suppress metastasis of Hela cells, and significantly inhibit the formation of HUVEC tubes. All these results suggest that 6-4 should be a promising candidate for the treatment of cancer.